InvestorsHub Logo
Followers 35
Posts 5775
Boards Moderated 0
Alias Born 02/20/2015

Re: akika post# 34802

Thursday, 03/01/2018 4:38:48 PM

Thursday, March 01, 2018 4:38:48 PM

Post# of 50157
Three years ago DCTH wasn't 12 months away from filing their CHEMSAT 2.0 NDA for FDA approval in a multi-million dollar global market.


Our primary research focus is on ocular melanoma liver metastases (mOM), intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC or primary liver), and certain other cancers that are metastatic to the liver. We believe the disease states we are investigating represent a multi-billion dollar global market opportunity and a clear unmet medical need.

http://phx.corporate-ir.net/phoenix.zhtml?c=123840&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTEyMDQxOTIxJkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3

Good night, sir. I am going offline for the evening.



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DCTH News